270 related articles for article (PubMed ID: 35753555)
1. Incidence and survival of patients with oligometastatic esophagogastric cancer: A multicenter cohort study.
Kroese TE; Christ SM; van Rossum PSN; Burger MDL; Buijs GS; Mühlematter U; Andratschke N; Ruurda JP; Hüllner M; Gutschow CA; van Hillegersberg R; Guckenberger M
Radiother Oncol; 2022 Aug; 173():269-276. PubMed ID: 35753555
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic radiotherapy or metastasectomy for oligometastatic esophagogastric cancer: A nationwide population-based cohort study.
Kroese TE; Jorritsma NKN; van Laarhoven HWM; Verhoeven RHA; Mook S; Haj Mohammad N; Ruurda JP; van Rossum PSN; van Hillegersberg R
Clin Transl Radiat Oncol; 2022 Nov; 37():109-115. PubMed ID: 36186924
[TBL] [Abstract][Full Text] [Related]
3. Metastasectomy or Stereotactic Body Radiation Therapy With or Without Systemic Therapy for Oligometastatic Esophagogastric Cancer.
Kroese TE; Buijs GS; Burger MDL; Ruurda JP; Mook S; Brosens LAA; van Rossum PSN; van Hillegersberg R
Ann Surg Oncol; 2022 Aug; 29(8):4848-4857. PubMed ID: 35381938
[TBL] [Abstract][Full Text] [Related]
4. Definition of oligometastatic esophagogastric cancer and impact of local oligometastasis-directed treatment: A systematic review and meta-analysis.
Kroese TE; van Laarhoven HWM; Nilsson M; Lordick F; Guckenberger M; Ruurda JP; D'Ugo D; Haustermans K; van Cutsem E; van Hillegersberg R; van Rossum PSN
Eur J Cancer; 2022 May; 166():254-269. PubMed ID: 35339868
[TBL] [Abstract][Full Text] [Related]
5. Liver oligometastatic disease in synchronous metastatic gastric cancer patients: a nationwide population-based cohort study.
Kroese TE; Takahashi Y; Lordick F; van Rossum PSN; Ruurda JP; Lagarde SM; van Hillegersberg R; Verhoeven RHA; van Laarhoven HWM
Eur J Cancer; 2023 Jan; 179():65-75. PubMed ID: 36509000
[TBL] [Abstract][Full Text] [Related]
6. Prognosis of Interval Distant Metastases After Neoadjuvant Chemoradiotherapy for Esophageal Cancer.
Kroese TE; Dijksterhuis WPM; van Rossum PSN; Verhoeven RHA; Mook S; Haj Mohammad N; Hulshof MCCM; van Berge Henegouwen MI; van Oijen MGH; Ruurda JP; van Laarhoven HWM; van Hillegersberg R
Ann Thorac Surg; 2022 Feb; 113(2):482-490. PubMed ID: 33610543
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the prognostic value of the ESTRO EORTC classification of oligometastatic disease in patients treated with stereotactic body radiotherapy: A retrospective single center study.
Willmann J; Vlaskou Badra E; Adilovic S; Ahmadsei M; Christ SM; van Timmeren JE; Kroeze SGC; Mayinger M; Guckenberger M; Andratschke N
Radiother Oncol; 2022 Mar; 168():256-264. PubMed ID: 35101466
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic radiotherapy in the management of oligometastatic and recurrent head and neck cancer: a single-center experience.
Mohamed AA; Goncalves M; Singh BP; Tometten M; Rashad A; Hölzle F; Hackenberg S; Eble M
Strahlenther Onkol; 2024 May; 200(5):400-408. PubMed ID: 38063900
[TBL] [Abstract][Full Text] [Related]
9. Oligometastatic Disease (OMD): The Classification and Practical Review of Prospective Trials.
Izmailov T; Ryzhkin S; Borshchev G; Boichuk S
Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958408
[TBL] [Abstract][Full Text] [Related]
10. Validation of the Prognostic Utility of ESTRO/EORTC Oligometastatic Disease Classification: A Secondary Analysis From the Population-Based Phase II SABR-5 Trial.
Baker S; Mou B; Jiang W; Liu M; Bergman AM; Schellenberg D; Alexander AS; Carolan H; Atrchian S; Berrang T; Bang A; Chng N; Matthews Q; Tyldesley S; Olson RA
Int J Radiat Oncol Biol Phys; 2022 Dec; 114(5):849-855. PubMed ID: 36302495
[TBL] [Abstract][Full Text] [Related]
11. Metastasis-directed Therapy in Prostate Cancer: Prognostic Significance of the ESTRO/EORTC Classification in Oligometastatic Bone Disease.
Nicholls L; Chapman E; Khoo V; Suh YE; Tunariu N; Wang Y; van As N
Clin Oncol (R Coll Radiol); 2022 Jan; 34(1):63-69. PubMed ID: 34756755
[TBL] [Abstract][Full Text] [Related]
12. Late metastatic presentation is associated with improved survival and delayed wide-spread progression after ablative stereotactic body radiotherapy for oligometastasis.
Chen X; Chen H; Poon I; Erler D; Badellino S; Biswas T; Dagan R; Foote M; Louie AV; Ricardi U; Sahgal A; Redmond KJ
Cancer Med; 2021 Sep; 10(18):6189-6198. PubMed ID: 34432390
[TBL] [Abstract][Full Text] [Related]
13. Management of Oligometastatic Disease in Esophagogastric Cancer: What Is the Evidence?
Hingorani M; Stubley H
Oncol Res Treat; 2023; 46(7-8):312-319. PubMed ID: 37331340
[TBL] [Abstract][Full Text] [Related]
14. Recurrence patterns and impact of brain metastases in synchronous single organ oligometastatic lung cancer following local ablative treatment - A multicenter analysis.
Frost N; Roeper J; Velthaus JL; Raspe M; Olive E; Schmittel A; Schmidt B; Wasilewski D; Onken J; Lüders H; Witzenrath M; Senger C; Böhmer D; Loges S; Griesinger F; Modest DP; Grohé C
Lung Cancer; 2022 Aug; 170():165-175. PubMed ID: 35803041
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer.
Fleckenstein J; Petroff A; Schäfers HJ; Wehler T; Schöpe J; Rübe C
BMC Cancer; 2016 Jun; 16():348. PubMed ID: 27255302
[TBL] [Abstract][Full Text] [Related]
16. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study.
Milano MT; Katz AW; Zhang H; Okunieff P
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):878-86. PubMed ID: 22172903
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic body radiation therapy in the treatment of cancer patients with oligometastatic disease: a real world study.
Stefanovic M; Calvet G; Pérez-Montero H; Esteve A; Bujalance MV; Navarro-Martín A; Fernández MDA; González FF; Borras SM; Borbalas AL; Fernandez MN; Garau MM; Calduch AL; Edo FG
Clin Transl Oncol; 2023 Jan; 25(1):199-206. PubMed ID: 36068449
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic Ablative Radiation Therapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer.
Zhang Y; Schoenhals J; Christie A; Mohamad O; Wang C; Bowman I; Singla N; Hammers H; Courtney K; Bagrodia A; Margulis V; Desai N; Garant A; Choy H; Timmerman R; Brugarolas J; Hannan R
Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):367-375. PubMed ID: 31377159
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Factors for Survival of Patients With Synchronous or Metachronous Brain Metastasis of Renal Cell Carcinoma.
Choi SY; Yoo S; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Kim CS
Clin Genitourin Cancer; 2017 Dec; 15(6):717-723. PubMed ID: 28552571
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic radiotherapy combined with immunotherapy or targeted therapy for metastatic renal cell carcinoma.
Kroeze SGC; Fritz C; Schaule J; Siva S; Kahl KH; Sundahl N; Blanck O; Kaul D; Adebahr S; Verhoeff JJC; Skazikis G; Roeder F; Geier M; Eckert F; Guckenberger M
BJU Int; 2021 Jun; 127(6):703-711. PubMed ID: 33113260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
